Merck Operating Income 2006-2019 | MRK

Merck annual/quarterly operating income history and growth rate from 2006 to 2019. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Merck operating income for the quarter ending June 30, 2019 was $3.458B, a 52.6% increase year-over-year.
  • Merck operating income for the twelve months ending June 30, 2019 was $12.382B, a 121.23% increase year-over-year.
  • Merck annual operating income for 2018 was $8.931B, a 31.4% increase from 2017.
  • Merck annual operating income for 2017 was $6.797B, a 23.6% increase from 2016.
  • Merck annual operating income for 2016 was $5.499B, a 27.14% decline from 2015.
Merck Annual Operating Income
(Millions of US $)
2018 $8,931
2017 $6,797
2016 $5,499
2015 $7,547
2014 $6,683
2013 $7,665
2012 $9,877
2011 $8,976
2010 $3,355
2009 $4,021
2008 $6,085
2007 $5,618
2006 $3,687
2005 $5,859
Merck Quarterly Operating Income
(Millions of US $)
Q2 2019 $3,458
Q1 2019 $3,408
Q4 2018 $2,852
Q3 2018 $2,664
Q2 2018 $2,266
Q1 2018 $1,149
Q4 2017 $2,036
Q3 2017 $146
Q2 2017 $2,532
Q1 2017 $2,083
Q4 2016 $-991
Q3 2016 $3,070
Q2 2016 $1,657
Q1 2016 $1,763
Q4 2015 $1,952
Q3 2015 $2,340
Q2 2015 $1,737
Q1 2015 $1,518
Q4 2014 $1,526
Q3 2014 $1,700
Q2 2014 $1,404
Q1 2014 $2,053
Q4 2013 $1,897
Q3 2013 $2,465
Q2 2013 $1,485
Q1 2013 $1,818
Q4 2012 $1,964
Q3 2012 $2,370
Q2 2012 $2,785
Q1 2012 $2,758
Q4 2011 $1,995
Q3 2011 $2,376
Q2 2011 $2,406
Q1 2011 $2,199
Q4 2010 $-441
Q3 2010 $1,420
Q2 2010 $1,443
Q1 2010 $933
Q4 2009 $-234
Q3 2009 $1,640
Q2 2009 $1,421
Q1 2009 $1,194
Q4 2008 $1,313
Q3 2008 $1,565
Q2 2008 $1,556
Q1 2008 $1,651
Q4 2007 $1,597
Q3 2007 $1,165
Q2 2007 $1,445
Q1 2007 $1,412
Q4 2006 $306
Q3 2006 $550
Q2 2006 $1,420
Q1 2006 $1,410
Q4 2005 $1,036
Q3 2005 $1,573
Q2 2005 $1,611
Q1 2005 $1,639
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $217.785B $42.294B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $346.681B 15.10
Roche Holding AG (RHHBY) Switzerland $237.118B 0.00
Novartis AG (NVS) Switzerland $205.270B 17.65
Pfizer (PFE) United States $191.651B 11.29
Novo Nordisk (NVO) Denmark $126.560B 21.00
AstraZeneca (AZN) United Kingdom $112.309B 22.51
Eli Lilly (LLY) United States $106.700B 19.91
Sanofi (SNY) France $104.896B 12.93
GlaxoSmithKline (GSK) United Kingdom $99.695B 12.60
AbbVie (ABBV) United States $95.259B 7.63
Bristol-Myers Squibb (BMY) United States $76.848B 10.90
Bayer (BAYRY) Germany $66.954B 9.76
H Lundbeck (HLUYY) Denmark $8.015B 11.57